Characterization of Musashi-1 in Pediatric Group 3 Medulloblastoma

Abstract

Pediatric medulloblastoma (MB) is the most common solid malignant brain neoplasm, with group 3 (G3) MB representing the most aggressive subgroup. Despite MYC amplification representing an independent poor prognostic factor in G3 MB, efforts to target the MYC pathway have met with limited therapeutic success. As such, alternative mediators of G3 MB continue to be sought. The RNA binding protein and neural stem cell determinant Musashi-1 (MSI1) has been implicated in a number of adult stem cells in various organs (e.g., brain, gut, ovaries/testes) with mounting evidence that MSI1 is an essential regulator of cancer stem cells (e.g., brain, gut, lung). Early studies in MB have shown MSI1 to be essential for tumour maintenance, however the direct interactions and specific mechanisms conferring tumours with high MSI1 expression (i.e., G3 MB) are yet to be determined. Here, I show MSI1 is an essential moderator of G3 MB in both a MYC amplified and p53 mutated (MP) mouse model of G3 MB and patient-derived xenograft (PDX) models. MSI1 inhibition resulted in an abrogation of tumour initiation in both models, translating to a significantly prolonged survival. To determine how MSI1 regulates the post-transcriptional landscape of human G3 MB, an unbiased multiplatform approach was undertaken, using enhanced cross-linking and immunoprecipitation (eCLIP), and differential analyses post-MSI1 inhibition at the transcriptome-, proteome-, and translatome-wide scale, revealing MSI1's key role in moderating G3 MB-associated cancer driving genes. In summary, employing innovational multi-platform integrative approach to stem cell cancer biology, I show the neural RNA binding protein MSI1, an essential master stem cell regulator, is hijacked from its normal neural developmental function to orchestrate the aberrant translational landscape of G3 MB.